Grace Koennecke

The European Medicines Agency's new standard procedure allows manufacturers to request advice from medical device expert panels

The 36-week trial was a randomized, double-masked, parallel-group, active-controlled, multicenter evaluating CLS-AX (axitinib injectable suspension) in participants with neovascular age-related macular degeneration.

The trial will feature the company’s product candidate, AXV101, focused on combating childhood blindness due to retinitis pigmentosa (RP) caused by Bardet-Biedl Syndrome 1 (BBS1).

The data will be presented virtually at Angiogenesis, Exudation, and Degeneration 2025 on February 8 and February 10, 2025.

Ashkan Abbey, MD, shares insights from the one-year data for the phase 2 DAVIO2 trial and the impact of tyrosine kinase inhibitors on reducing treatment burden.

The company offers year-round educational services on the conditions, using this month in particular to guide patients to needed resources.

The scientific outputs from MACUSTAR’s study could impact more than 200 million patients with AMD globally

The program will deliver a range of high-quality access and affordability services for retina specialists.

The companies will work together by using the codon-optimized BBS1 AAV9 vector to minimize the vision loss caused by the genetic defects in the BBS1 gene.

The funding will support activities like formal pharmacology and toxicology testing.

The new funding will allow the company to complete its ongoing Phase 2 trial of proprietary nanomedicine, migaldendranib, in patients with wet AMD and DME

Valerie Biousse, MD, from the Emory University in Atlanta, Georgia, shared insights on how ocular imaging in the emergency department can provide timely, accurate diagnosis while also benefiting the on-call ophthalmologists.

Glenn C. Yiu, MD, PhD, from the University of California David, shared insights from his presentation on suprachoroidal drug delivery in the real world at this year's AAO meeting held in Chicago, Illinois.

Sujay Jadhav, CEO of Verana Health, a digital health company dedicated to revolutionizing patient care and clinical research through real-world data (RWD), provides an overview of new FDA guidance.

The CPT code is the first to report photobiomodulation therapy in retinal disease.

KIO-30 is a small molecule photoswitch that selectively confers light-sensing capabilities to retinal ganglion cells following the degeneration of photoreceptors in inherited retinal diseases.